Abstract: Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

Abstract: Sewage sludge is dewatered to a cake-like state. The viscosity of the sludge is lowered by admixing a quantity of urea, urea-ammonium-nitrate, or other nitrogen-containing material, in with the dewatered sludge. The treatment also removes pathogens, and renders the product suitable for use as a fertilizer.

Abstract: A system and method for addressing RLC unrecoverable errors experienced by User Equipment (UE) in a wireless network help the network to resolve the errors without shifting the UE into an Idle mode and dropping voice calls. A measurement event provides the buffer occupancy and identifies the affected radio bearer to the network. If the state of the bearer is not changed, the UE provides a Signaling Connection Release Indication message or a Radio Bearer Release Indication message to the network, the latter message identifying the radio bearer to be released without taking down the entire signaling connection for the domain.

Abstract: An automation process verifies that a test bed includes a set of devices specified by at least one script which are to be executed by the automation process on the test bed. The test bed is locked and the set of devices is allocated to the automation process. Performance data collection and logging for the set of devices is started and the at least one script is executed on the set of devices. After executing the at least one script, the set of devices is de-allocated and the test bed is unlocked. A notification is generated indicating that the at least one script has been executed.

Abstract: Provided are compounds of Formula (I): wherein R2, R3, R13, L and D2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

Abstract: Disclosed herein are cylinder forming apparatuses for making nonwoven webs. In one embodiment, a cylinder forming apparatus has a first source configured to dispense a first fluid flow stream, and a second source configured to dispense a second fluid flow stream, wherein at least the first fluid flow stream comprises a fiber; an arcuate mixing partition downstream from the one or more sources, the arcuate mixing partition positioned between the first and second flow streams, the apparatus defining one or more openings that permit fluid communication between the two flow streams; and a cylindrical receiving region situated downstream from the sources and proximal to the first flow stream and designed to receive at least a combined flow stream and form a nonwoven web by collecting fiber from the combined flow stream. Methods of using the apparatuses are also disclosed.

Abstract: Methods and apparatuses for forming a nonwoven web are described herein. The apparatus includes a mixing partition defining one or more openings therein that permit fluid communication between two fluid flow streams, at least one of which includes a fiber. The apparatus also includes an enclosed region surrounding at least a portion of the mixing partition. The enclosed region is adapted to provide an applied pressure to a fluid flow stream to urge the stream through one or more of the openings in the mixing partition. The apparatus also includes a receiving region designed to receive at least a combined flow stream and form a nonwoven web by collecting fiber from the combined flow stream.

Abstract: Provided are compounds of Formula (I): wherein R2, R3, R13, L and D2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

Abstract: Provided is a method and apparatus for scanning for cells in a cellular network. Upon an event triggering scanning while a mobile device resides in a current cell of a cellular network, the mobile device scans for at least one cell purported by the cellular network to neighbor the current cell. In accordance with an embodiment of the disclosure, the mobile device also scans for at least one other cell that is not purported by the cellular network to neighbor the current cell. This occurs promptly without waiting for completion of the scanning for cells purported by the cellular network to neighbor the current cell. Advantageously, in the case of poor network planning, the mobile device might promptly acquire a cell that is not purported by the cellular network to neighbor the current cell but nonetheless offers coverage in vicinity of the current cell.

Abstract: A process for producing monodispersed carbon spheres comprising the steps of mixing supercritical-carbon dioxide fluid under pressure with a solvent in an inert atmosphere; heating the mixture in to a temperature to carbonise the solvent; and modulating the pressure to the heated mixture to produce carbon spheres. Subsequent addition of an organometallic precursor can be used to induce the nucleation and growth of nanocrystals across the surface of the spheres.

Abstract: Embodiments of the present invention provide mechanisms for improving storage consumption on a sequential access medium, such as a physical tape, by preferably storing one instance of a data block of a backup data set on the tape media. When another instance of a data block is received having the same pattern as the stored data block, rather than storing the data block itself, a reference to the data block is stored on the sequential access medium. When data are restored, data blocks are cached at a block store on a storage device(s) having a faster seek time than the tape. When a reference to a previously stored data block is read from the tape, rather than re-winding the tape to search for the data block on the tape (which might take a long time to locate), the referenced data block can be found on the storage device having a faster seek time than the tape media.

Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —S—R14; and other substituents are as defined in the specification.

Abstract: A storage management application of a storage array is operable to create a new volume on the storage device array, and to automatically configure, responsive to user selection of an application protection profile, data protection services for application data to be stored on the volume, and/or, responsive to user selection of an application performance profile, application specific performance parameters. The application protection profile specifies scheduling and replication of snapshots for application data to be stored on the volume, and the application performance profile specifies performance parameters such as setting a block size, enabling or modifying a data caching algorithm, turning on or modifying data compression, etc. The scheduling, replication and/or application performance may be managed by a daemon associated with the storage management application which communicates with an agent associated with an application server on which the application executes.

Abstract: This invention relates to an improved and scalable process for the preparation of substantially pure palonosetron and its acid addition salts, in particular hydrochloride (I) which comprises of, (a) converting intermediate (IIa) as such or as its freebase (II) to a crude mixture of diastereomeric palonosetrons (VIII) or (VIIIa) contaminated with varying amounts of unconverted intermediate (II) or (IIa) via hydrogenation under pressure with an appropriately chosen hydrogenation catalyst in an suitable organic solvent. (b) making the resulting crude mixture of diastereomeric palonosetrons (VIII) or (VIIIa) contaminated with varying amounts of unconverted intermediate (II) or (IIa) substantially free from (II) or (IIa) via halogenation reaction.

Abstract: Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

Abstract: This invention relates to an improved process for preparing substantially pure simvastatin (I), chemically known as (1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2-H-pyran-2-yl]ethyl]-3 ,7-dimeth-yl-1,2,3,7,8,8a-Hexahydronaphthalen-1-yl2,2-dimethyl butanoate, which comprises of: a) treating lovastatin (II) with an alkali metal hydroxide in a chosen suitable alcoholic solvent followed by relactonization to obtain the diol lactone intermediate (III) in a single vessel. b) selective silylation of 4-hydroxy group of diol lactone intermediate (III) with a chosen suitable silylating reagent to obtain mono silylated intermediate diol lactone (IV).

Abstract: Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes meilitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

Abstract: Provided are compounds of formula I wherein R2, L, Z, Y, G and R1 are as defined herein, that are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

Abstract: Sewage sludge that has been de-watered to 25% solids is subjected to a combination of shearing and heating that liquefies the sludge, and drops its viscosity to below 12,000 cP. The fact of liquefaction prepares the sludge such that subsequent drying can be done more cost-effectively than hitherto. After drying, the dried sludge can be incinerated.

Abstract: The present invention relates to novel crystalline forms of the platelet aggregation inhibitor (+)-(S)-methyl-2-(2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetate, clopidogrel (1), in the form of hydrogen bromide salts, identified as polymorph forms 1, 2 and 3. The present invention further relates to processes for preparing such forms, pharmaceutical compositions comprising such forms, and uses for such forms and compositions. The pharmaceutical compositions may be used, in particular, for inhibiting platelet aggregation or for treating, preventing or managing thrombosis, atherothrombosis, an atherothrombotic event, ischaemic stroke, myocardial infarction, non-Q-wave myocardial infarction, atherosclerosis, peripheral arterial disease, or unstable angina. The present invention also relates to methods of treating said disorders. Formula (1).